Lymphedema Treatment Registry

Multi Center Lymphedema Treatment Registry (LET) Study

Patients with breast cancer related lymphedema (clinical stage 0-2) will include in this study. Patients will take their demographic and clinical history and will evaluate with measurements of extremity volumes, body mass index, quality of life status and image studies (lymphoscintigraphy, Ultrasonography (USG), Indocyanine Green (ICG) Lymphograph or magnetic resonance imaging (MRI)) before and after the complete decongestive therapy. Outcome measurements such as limb volume, quality of life questionnaire and USG will repeat every 6,12,18, 24 months.

Patients with breast cancer related lymphedema (clinical stage 0-2) will include in this study. Patients will take their demographic and clinical history and will evaluate with measurements of extremity volumes, body mass index, quality of life status and image studies (lymphoscintigraphy, USG, ICG or MRI) before and after the complete decongestive therapy (CDT). Outcome measurements such as limb volume, quality of life questionnaire and USG will repeat every 6,12,18, 24 months.

Group 1: CDT Group 2: CDT + PO ketoprofen +Local ketoprofen gel Group 3: CDT + Local ketoprofen gel

Inclusion Criteria:

• Breast cancer
• Lymphedema more than 6 months
• Lymphedema stage 0-2
• Completed treatment (CT-RT)

Exclusion Criteria:

• Stage 3 lymphedema
• Cardiovasculary disease
• Hepatic disease
• Kidney disease
• Cerebrovascular event
• Metastasis
• Gastritis
• Infection
• Smoking
• Active cancer
• Bleeding history